Use of flunarizine and method for controlling number of intercellular mitochondria
US-2024325381-A1 · Oct 3, 2024 · US
Treatment of insulin resistance through inhibitors of transcription factor TSC22D4
US9879258B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9879258-B2 |
| Application number | US-201414787416-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 17, 2014 |
| Priority date | Jun 17, 2013 |
| Publication date | Jan 30, 2018 |
| Grant date | Jan 30, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to modulators, in particular inhibitors, of TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in mammal. The present invention further relates to screening methods in order to identify these modulators, the use of modulators as identified in the diagnosis of these diseases, as well as kits, comprising materials for performing the methods according to the present invention.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treatment of insulin resistance and/or type 2 diabetes and/or for improving insulin sensitivity, wherein said method comprises administering to a subject in need of such treatment and/or improvement, a pharmaceutical composition comprising a modulator that is specific for TSC22D4 function and/or expression and wherein said modulator is an oligonucleotide; and a pharmaceutically acceptable excipient. 2. The method, according to claim 1 , wherein said pharmaceutical composition is administered orally, rectally, transmucosally, transdermally, intestinally, parenterally, intramuscularly, intrathecally, direct intraventricularly, intravenously, intraperitoneally, intranasally, intraocularly, or subcutaneously.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
- G01N33/5008Primary
for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9879258B2 cover?
- The present invention relates to modulators, in particular inhibitors, of TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in mammal. The present invention further relates to screening methods in order to identify these modulators, the use of modulator…
- Who is the assignee on this patent?
- Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Ruprecht-Karls-Universitaet Heidelberg, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5008. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).